26 records found.
Dec 17, 2019
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day
Apr 02, 2019
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
Feb 07, 2019
Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I
Feb 07, 2019
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
Feb 01, 2019
Sangamo Therapeutics To Host Conference Call To Review Interim Results From Phase 1/2 CHAMPIONS And EMPOWERS Studies For MPS II And MPS I
Jan 04, 2019
Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019
Dec 17, 2018
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
Dec 03, 2018
Sangamo Announces Completion Of TxCell Acquisition
Nov 21, 2018
Global Genome Editing Market 2017-2018 & 2025: Opportunities in Emerging Markets For Precision and Regenerative Medicines
Oct 17, 2018
Global Gene Editing and Gene Therapy Market Research 2018: A New Wave of Gene Therapy Treatments to Revolutionize Treatment of Inherited Diseases
Sep 05, 2018
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
Jul 23, 2018
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I
Jun 04, 2018
Sangamo Announces U.K. Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments SB-318 For MPS I And SB-913 For MPS II
May 14, 2018
DNA Editing Market will retain double digit growth to beat the revenue of $7.5 billion by 2024
May 01, 2018
Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy
Apr 04, 2018
Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program
Feb 28, 2018
Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatment For Hemophilia B
Feb 22, 2018
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Feb 13, 2018
Sangamo Presents Oncology Genome Editing Capabilities at Keystone Symposium on Emerging Cellular Therapies
Feb 07, 2018
Case Western Reserve and Sangamo Therapeutics Announce $11 Million NIH Grant for Study of Gene-Edited T Cells for Viral Eradication of HIV

Pages